KAF156 is a pipeline drug in development by Novartis for the purpose of treating malaria. malaria. It belongs to the class of the imidazolopiperazines. It has shown activity against the Plasmodium falciparum and Plasmodium vivax forms of the malaria parasite.
Contents
Commercialization
Novartis is an international drug company based in Switzerland that is developing KAF156 as a drug for the treatment of Malaria. This drug was identified by a high throughput screen of over 2 million compounds. This drug is being developed with support from the Bill and Melinda Gates foundation via their Medicine for Malaria Venture. It will also be a part of the Novartis Malaria Initiative which has been providing 750 million treatments without producing any profit for the larger company.
Novartis is a strong company that reported a net income of 17.8 million US dollars in profit in the 2015 fiscal year an improvement of 73% from the previous year.
Intellectual Property
KAF156 is protected by the granted United States Patent 20130281403 held by the inventors, Arnab Chatterjee, Advait Nagle, Tao Wu, David Tully, and Kelli Kuhen, and filed June 7, 2013. There are previous US patent applications but only this one has been granted.
Clinical Development
The lead product was published in 2012 as a leader of the imidazolopiperazine class. This was followed by studies in animal models published in 2014. Preclinical study found on significant in vitro safety liabilities. A Phase 1 study found some gastrointestinal and neurological effects but these were self-limited in 70 healthy males and established dosing for a future Phase 2 Trial.
The just completed Phase 2 Trial was completed with 4 study locations in Thailand and one study location in Vietnam. This study looked at the effect of 400 mg given daily for 3 days as well as a single 800 mg dose. In the 21 Patients who received a single 800 mg dose 67% of patients cleared the infection which is comparable to other antimalarial medications. More than half of the patients had some reported adverse event and the rate was higher in patients who received a single 800 mg dose over patients who received 3 400 mg doses. The most common effect was Asymptomatic Bradycardia where patients heart rates fell below 60 BMP. Other reported events include hypokalemia, elevated liver enzymes as well as anemia.
Pharmacology
The mechanism of this drug is currently unknown. Loss of protein PfCARL with 7 transmembrane section and an unknown role in the parasite but it is not know if this protein is the target of KAF156, a transporter of the drug, or what role it plays.